Journal of Medicinal Chemistry
Article
(11) Marek, M.; Oliveira, G.; Pierce, R. J.; Jung, M.; Sippl, W.;
Romier, C. Drugging the Schistosome Zinc-Dependent HDACs:
Current Progress and Future Perspectives. Future Med. Chem. 2015, 7,
783−800.
synthesis, and biological activity of NCC149 derivatives as histone
deacetylase 8-selective inhibitors. ChemMedChem 2014, 9, 657−664.
(31) Andrews, K. T.; Walduck, A.; Kelso, M. J.; Fairlie, D. P.; Saul, A.;
Parsons, P. G. Anti-Malarial Effect of Histone Deacetylation Inhibitors
and Mammalian Tumour Cytodifferentiating Agents. Int. J. Parasitol.
2000, 30, 761−768.
(12) Hotez, P. J.; Pecoul, B. Manifesto” for Advancing the Control
and Elimination of Neglected Tropical Diseases. PLoS Neglected Trop.
Dis. 2010, 4, e718.
(32) Oger, F.; Dubois, F.; Caby, S.; Noel, C.; Cornette, J.; Bertin, B.;
̈
Capron, M.; Pierce, R. J. The Class I Histone Deacetylases of the
Platyhelminth Parasite Schistosoma mansoni. Biochem. Biophys. Res.
Commun. 2008, 377, 1079−1084.
(33) Dubois, F.; Caby, S.; Oger, F.; Cosseau, C.; Capron, M.;
Grunau, C.; Dissous, C.; Pierce, R. J. Histone Deacetylase Inhibitors
Induce Apoptosis, Histone Hyperacetylation and up-Regulation of
Gene Transcription in Schistosoma mansoni. Mol. Biochem. Parasitol.
2009, 168, 7−15.
(13) Schafer, S.; Jung, M. Chromatin Modifications as Targets for
̈
New Anticancer Drugs. Arch. Pharm. 2005, 338, 347−357.
(14) Pierce, R. J.; Dubois-Abdesselem, F.; Lancelot, J.; Andrade, L.;
Oliveira, G. Targeting Schistosome Histone Modifying Enzymes for
Drug Development. Curr. Pharm. Des. 2012, 18, 3567−3578.
(15) Andrews, K. T.; Haque, A.; Jones, M. K. HDAC Inhibitors in
Parasitic Diseases. Immunol. Cell Biol. 2012, 90, 66−77.
(16) Ouaissi, M.; Ouaissi, A. Histone Deacetylase Enzymes as
Potential Drug Targets in Cancer and Parasitic Diseases. J. Biomed.
Biotechnol. 2006, 2006, 13474.
(34) Lancelot, J.; Caby, S.; Dubois-Abdesselem, F.; Vanderstraete,
M.; Trolet, J.; Oliveira, G.; Bracher, F.; Jung, M.; Pierce, R. J.
Schistosoma mansoni sirtuins: characterization and potential as
chemotherapeutic targets. PLoS Neglected Trop. Dis. 2013, 7, e2428.
(35) Nakagawa, M.; Oda, Y.; Eguchi, T.; Aishima, S.-I.; Yao, T.;
Hosoi, F.; Basaki, Y.; Ono, M.; Kuwano, M.; Tanaka, M.; Tsuneyoshi,
M. Expression Profile of Class I Histone Deacetylases in Human
Cancer Tissues. Oncol. Rep. 2007, 18, 769−774.
(17) Grunstein, M. Histone Acetylation in Chromatin Structure and
Transcription. Nature 1997, 389, 349−352.
(18) Peserico, A.; Simone, C. Physical and Functional HAT/HDAC
Interplay Regulates Protein Acetylation Balance. J. Biomed. Biotechnol.
2011, 2011, 371832.
(19) Yang, X. J.; Seto, E. The Rpd3/Hda1 Family of Lysine
Deacetylases: From Bacteria and Yeast to Mice and Men. Nat. Rev.
Mol. Cell Biol. 2008, 9, 206−218.
(20) North, B. J.; Verdin, E. Sirtuins: Sir2-Related NAD-Dependent
Protein Deacetylases. Genome Biol. 2004, 5, 224.
(36) Marek, M.; Kannan, S.; Hauser, A. T.; Moraes Mourao, M.;
̃
Caby, S.; Cura, V.; Stolfa, D. A.; Schmidtkunz, K.; Lancelot, J.;
Andrade, L.; Renaud, J. P.; Oliveira, G.; Sippl, W.; Jung, M.; Cavarelli,
J.; Pierce, R. J.; Romier, C. Structural Basis for the Inhibition of
Histone Deacetylase 8 (HDAC8), a Key Epigenetic Player in the
Blood Fluke Schistosoma mansoni. PLoS Pathog. 2013, 9, e1003645.
(37) Stolfa, D.; Marek, M.; Lancelot, J.; Hauser, A.-T.; Walter, A.;
Leproult, E.; Melesina, J.; Rumpf, T.; Wurtz, J.-M.; Cavarelli, J.; Sippl,
W.; Pierce, R. J.; Romier, C.; Jung, M. Molecular Basis for the
Antiparasitic Activity of a Mercaptoacetamide Derivative That Inhibits
Histone Deacetylase 8 (HDAC8) from the Human Pathogen
Schistosoma mansoni. J. Mol. Biol. 2014, 426, 3442−3453.
(21) Cho, Y. S.; Whitehead, L.; Li, J.; Chen, C. H. T.; Jiang, L.;
Vogtle, M.; Francotte, E.; Richert, P.; Wagner, T.; Traebert, M.; Lu,
̈
Q.; Cao, X.; Dumotier, B.; Fejzo, J.; Rajan, S.; Wang, P.; Yan-Neale, Y.;
Shao, W.; Atadja, P.; Shultz, M. Conformational Refinement of
Hydroxamate-Based Histone Deacetylase Inhibitors and Exploration
of 3-Piperidin-3-Ylindole Analogues of Dacinostat (LAQ824). J. Med.
Chem. 2010, 53, 2952−2963.
(22) Marks, P.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.;
Kelly, W. K. Histone Deacetylases and Cancer: Causes and Therapies.
Nat. Rev. Cancer 2001, 1, 194−202.
(38) Kannan, S.; Melesina, J.; Hauser, A.; Chakrabarti, A.; Heimburg,
T.; Schmidtkunz, K.; Walter, A.; Marek, M.; Pierce, R. J.; Romier, C.;
Jung, M.; Sippl, W. Discovery of Inhibitors of Schistosoma mansoni
HDAC8 by Combining Homology Modeling, Virtual Screening, and
in Vitro Validation. J. Chem. Inf. Model. 2014, 54, 3005−3019.
(39) Chakrabarti, A.; Oehme, I.; Witt, O.; Oliveira, G.; Sippl, W.;
Romier, C.; Pierce, R. J.; Jung, M. HDAC8: A Multifaceted Target for
Therapeutic Interventions. Trends Pharmacol. Sci. 2015, 36, 481−92.
(23) Ito, K.; Ito, M.; Elliott, W. M.; Cosio, B.; Caramori, G.; Kon, O.
M.; Barczyk, A.; Hayashi, S.; Adcock, I. M.; Hogg, J. C.; Barnes, P. J.
Decreased Histone Deacetylase Activity in Chronic Obstructive
Pulmonary Disease. N. Engl. J. Med. 2005, 352, 1967−1976.
(24) Mukherjee, P.; Pradhan, A.; Shah, F.; Tekwani, B. L.; Avery, M.
A. Structural Insights into the Plasmodium Falciparum Histone
Deacetylase 1 (PfHDAC-1): A Novel Target for the Development of
Antimalarial Therapy. Bioorg. Med. Chem. 2008, 16, 5254−5265.
(25) Giannini, G.; Cabri, W.; Fattorusso, C.; Rodriquez, M. Histone
Deacetylase Inhibitors in the Treatment of Cancer: Overview and
Perspectives. Future Med. Chem. 2012, 4, 1439−1460.
(26) Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat:
development of this histone deacetylase inhibitor as an anticancer
drug. Nat. Biotechnol. 2007, 25, 84−90.
(27) Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner,
E.; Buggy, J. J. A novel histone deacetylase 8 (HDAC8)-specific
inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia
2008, 22, 1026−1034.
́
(40) Rodrigues, D. A.; Ferreira-Silva, G. A.; Ferreira, A. C. S.;
Fernandes, R. A.; Kwee, J. K.; Sant’Anna, C. M. R.; Ionta, M.; Fraga, C.
A. M. Design, Synthesis, and Pharmacological Evaluation of Novel N-
Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual
Inhibitors. J. Med. Chem. 2016, 59, 655−670.
(41) Wang, L.; Kofler, M.; Brosch, G.; Melesina, J.; Sippl, W.;
Martinez, E. D.; Easmon, J. 2-Benzazolyl-4-Piperazin-1-Ylsulfonylben-
zenecarbo-hydroxamic Acids as Novel Selective Histone Deacetylase-6
Inhibitors with Antiproliferative Activity. PLoS One 2015, 10,
e0134556.
(42) Lobera, M.; Madauss, K. P.; Pohlhaus, D. T.; Wright, Q. G.;
Trocha, M.; Schmidt, D. R.; Baloglu, E.; Trump, R. P.; Head, M. S.;
Hofmann, G. A.; Murray-Thompson, M.; Schwartz, B.; Chakravorty,
S.; Wu, Z.; Mander, P. K.; Kruidenier, L.; Reid, R. A.; Burkhart, W.;
Turunen, B. J.; Rong, J. X.; Wagner, C.; Moyer, M. B.; Wells, C.;
Hong, X.; Moore, J. T.; Williams, J. D.; Soler, D.; Ghosh, S.; Nolan, M.
A. Selective class IIa histone deacetylase inhibition via a nonchelating
zinc-binding group. Nat. Chem. Biol. 2013, 9, 319−325.
(28) Suzuki, T.; Ota, Y.; Ri, M.; Bando, M.; Gotoh, A.; Itoh, Y.;
Tsumoto, H.; Tatum, P. R.; Mizukami, T.; Nakagawa, H.; Iida, S.;
Ueda, R.; Shirahige, K.; Miyata, N. Rapid Discovery of Highly Potent
and Selective Inhibitors of Histone Deacetylase 8 Using Click
Chemistry to Generate Candidate Libraries. J. Med. Chem. 2012, 55,
9562−9575.
(29) Huang, W. J.; Wang, Y. C.; Chao, S. W.; Yang, C. J.; Chen, L.
C.; Lin, M. H.; Hou, W. C.; Chen, M. Y.; Lee, T. L.; Yang, P.; Chang,
C. I. Synthesis and biological evaluation of ortho-aryl N-
hydroxycinnamides as potent histone deacetylase (HDAC) 8 iso-
form-selective inhibitors. ChemMedChem 2012, 7, 1815−1824.
(30) Suzuki, T.; Muto, N.; Bando, M.; Itoh, Y.; Masaki, A.; Ri, M.;
Ota, Y.; Nakagawa, H.; Iida, S.; Shirahige, K.; Miyata, N. Design,
(43) Olson, D. E.; Wagner, F. F.; Kaya, T.; Gale, J. P.; Aidoud, N.;
Davoine, E. L.; Lazzaro, F.; Weïwer, M.; Zhang, Y. L.; Holson, E. B.
Discovery of the First Histone Deacetylase 6/8 Dual Inhibitors. J. Med.
Chem. 2013, 56, 4816−4820.
(44) Tang, W.; Luo, T.; Greenberg, E. F.; Bradner, J. E.; Schreiber, S.
L. Discovery of histone deacetylase 8 selective inhibitors. Bioorg. Med.
Chem. Lett. 2011, 21, 2601−2605.
2434
J. Med. Chem. 2016, 59, 2423−2435